Skip to main content
. 2022 Jul 14;150(3):594–603.e2. doi: 10.1016/j.jaci.2022.06.020

Fig 3.

Fig 3

DNA damage in PBMCs from patients with COVID-19. A, PBMCs from a patient with COVID-19 whose monocytes induce DNA damage in bystander BJ cells spontaneously present with γ-H2AX foci. PBMCs from an HD treated with camptothecin or not treated were used as positive and negative controls, respectively. B, Percentages of PBMCs harboring γ-H2AX foci in HDs, non-ICU patients (non-ICU), and ICU patients (ICU). Kruskal-Wallis test P = .002. C, PBMCs from a patient with COVID-19 whose monocytes induce DNA damage in bystander BJ cells spontaneously present with 53BP1 foci. PBMCs from an HD treated with camptothecin or not treated were used as positive and negative controls, respectively. D, Annexin V expression on peripheral blood CD4+ T cells and CD8+ T cells of HDs, non-ICU patients (non-ICU), and ICU patients (ICU). One-way ANOVA test P < .001 for CD4+ T cells and P < .001 for CD8+ T cells. E, Correlation between the intensity of DNA damage in PBMC and lymphocyte counts. The intensity of DNA damage in PBMCs is expressed as the ratio of the percentage of patient PBMCs presenting γ-H2AX foci to the percentage of HD PBMCs presenting γ-H2AX foci.